Newswire (Published: Tuesday, August 27, 2019, Received: Tuesday, August 27, 2019, 5:22:46 PM CDT)

Word Count: 386

2019 AUG 27 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Daily -- Investigators discuss new findings in Oncology - Prostate Cancer. According to news originating from Suita Osaka, Japan, by NewsRx correspondents, research stated, “Prostate cancer is the most common type of cancer and the leading cause of cancer deaths among men in many countries. Preventing progression is a major concern for prostate cancer patients on active surveillance, patients with recurrence after radical therapies, and patients who acquired resistance to systemic therapies.”

Financial support for this research came from Japan Society for the Promotion of Science.

Our news journalists obtained a quote from the research from the Osaka University Graduate School of Medicine, “Inflammation, which is induced by various factors such as infection, microbiome, obesity, and a high-fat diet, is the major etiology in the development of prostate cancer. Inflammatory cells play important roles in tumor progression. Various immune cells including tumor-associated neutrophils, tumor-infiltrating macrophages, myeloid-derived suppressor cells, and mast cells promote prostate cancer via various intercellular signaling. Further basic studies examining the relationship between the inflammatory process and prostate cancer progression are warranted. Interventions by medications and diets to control systemic and/or local inflammation might be effective therapies for prostate cancer progression. Epidemiological investigations and basic research using human immune cells or mouse models have revealed that non-steroidal anti-inflammatory drugs, metformin, statins, soy isoflavones, and other diets are potential interventions for preventing progression of prostate cancer by suppressing inflammation.”

According to the news editors, the research concluded: “It is essential to evaluate appropriate indications and doses of each drug and diet.”

For more information on this research see: Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer. Cancers, 2019;11(8):1153.

The news correspondents report that additional information may be obtained from K. Fujita, Dept. of Urology, School of Medicine, Suita, Osaka 565-0871, Japan. Additional authors for this research include K. Fujita, M. Matsushita and N. Nonomura.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.3390/cancers11081153. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Places

Eastern Asia
Japan
Asia
Osaka
Suita

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Inflammatory Diseases
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Medical Specialties and Practices
            Urology
      Treatments and Therapies
            Medicinal Drugs
Life and Society
      Education